In the preceding three months, 4 analysts have released ratings for Entrada Therapeutics (NASDAQ:TRDA), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 2 | 0 | 0 | 0 |
Last 30D | 1 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.75, a high estimate of $28.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 5.81% from the previous average price target of $21.50.